Your browser doesn't support javascript.
loading
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.
Yamaoka, Toshimitsu; Tsurutani, Junji; Sagara, Hironori; Ohmori, Tohru.
Affiliation
  • Yamaoka T; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
  • Tsurutani J; Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Sagara H; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
  • Ohmori T; Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Transl Lung Cancer Res ; 9(5): 2178-2183, 2020 Oct.
Article in En | MEDLINE | ID: mdl-33209639
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2020 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Transl Lung Cancer Res Year: 2020 Document type: Article Affiliation country: Japan